Inspire Medical Systems, Inc. to Report Third Quarter 2025 Financial Results on November 3, 2025
MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the...
News
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
Exploring Strategic Partnerships to Expand Platform Beyond Reproductive HealthSAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:...
Hipp Health Raises $6.2 Million in Seed Funding
Company Will Utilize Funds for Product Expansion, AI Investments, and Team GrowthSAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Hipp...
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational...
Valitor Announces Upcoming Presentation at the Eyecelerator Conference Hosted in Conjunction with the American Academy of Ophthalmology (AAO) 2025 Annual Meeting
Preclinical tolerability and retinal distribution data further support a 6-month dosing interval to treat wet AMDBERKELEY, Calif., Oct. 06, 2025...
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to...
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company...
Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
LOUISVILLE, Ky., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a...
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain...
Kraig Biocraft Laboratories Announces Production Expansion
ANN ARBOR, Mich., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials...
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into...
Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH
BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics...
Soleo Health Named Pioneer in URAC’s Leaders in Performance Measurement
FRISCO, Texas, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy...
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs
Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing program, ABO-101 for primary...
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
Company to present three posters at SITC Annual Meeting 2025BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:...
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes
Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary...
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results...
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute...
USA Pickleball Grants Official Approval and Certification for J-Star’s First In-House Pickleball Paddle, Horizon
TAICHUNG CITY, Taiwan, Oct. 06, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a...